{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:40:09Z","timestamp":1790894409957,"version":"4.1.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.2312","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T11:02:27Z","timestamp":1647342147000},"page":"e222312","source":"Crossref","is-referenced-by-count":35,"title":["Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis"],"prefix":"10.1001","volume":"5","author":[{"given":"Runsheng","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Columbia University Irving Medical Center, New York, New York"},{"name":"Garden State Rheumatology Consultants, Union, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland"},{"name":"now with AstraZeneca, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Ward","sequence":"additional","affiliation":[{"name":"Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"issue":"26","key":"zoi220101r1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis.","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi220101r2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.v71.10","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis.","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"zoi220101r3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi220101r4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3899\/jrheum.170224","article-title":"Comparative efficacy of tumor necrosis factor-a inhibitors in ankylosing spondylitis: a systematic review and bayesian network metaanalysis.","volume":"45","author":"Wang","year":"2018","journal-title":"J Rheumatol"},{"issue":"6","key":"zoi220101r5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi220101r6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol"},{"issue":"8","key":"zoi220101r7","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.141278","article-title":"Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials.","volume":"42","author":"Baraliakos","year":"2015","journal-title":"J Rheumatol"},{"issue":"11","key":"zoi220101r8","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry.","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi220101r9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000917","article-title":"Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.","volume":"5","author":"Sieper","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"zoi220101r10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4081\/reumatismo.2014.756","article-title":"Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFa drugs.","volume":"66","author":"Perrotta","year":"2014","journal-title":"Reumatismo"},{"issue":"4","key":"zoi220101r11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","article-title":"Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.","volume":"57","author":"Yahya","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"zoi220101r12","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"zoi220101r13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/acr.v69.2","article-title":"Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis.","volume":"69","author":"Liu","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"zoi220101r14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","article-title":"Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.","volume":"19","author":"Micheroli","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"zoi220101r15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-a inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"zoi220101r16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi220101r17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"zoi220101r18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10979-005-6832-7","article-title":"Comparing effect sizes in follow-up studies: ROC area, Cohen\u2019s d, and r.","volume":"29","author":"Rice","year":"2005","journal-title":"Law Hum Behav"},{"issue":"6-7","key":"zoi220101r19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/13854046.2017.1335438","article-title":"Sensitivity and specificity should never be interpreted in isolation without consideration of other clinical utility metrics.","volume":"31","author":"Lange","year":"2017","journal-title":"Clin Neuropsychol"},{"issue":"1","key":"zoi220101r20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random Forests.","volume":"45","author":"Breiman","year":"2001","journal-title":"Machine Learning"},{"issue":"9","key":"zoi220101r21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Bootstrap confidence intervals: when, which, what? a practical guide for medical statisticians.","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"issue":"85","key":"zoi220101r22","first-page":"2825","article-title":"Scikit-learn: machine learning in Python.","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J Machine Learning Res"},{"issue":"7","key":"zoi220101r23","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"zoi220101r24","first-page":"2030","article-title":"Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.","volume":"35","author":"Maksymowych","year":"2008","journal-title":"J Rheumatol"},{"issue":"3","key":"zoi220101r25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi220101r26","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"zoi220101r27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"zoi220101r28","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi220101r29","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.v58:11","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"zoi220101r30","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"zoi220101r31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE Study.","volume":"45","author":"Deodhar","year":"2018","journal-title":"J Rheumatol"},{"issue":"2","key":"zoi220101r32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"zoi220101r33","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/rheumatology\/keaa241","article-title":"Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable.","volume":"60","author":"Ortolan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"zoi220101r34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","article-title":"Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry.","volume":"55","author":"Glintborg","year":"2016","journal-title":"Rheumatology (Oxford)"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2790101\/wang_2022_oi_220101_1646767776.23203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T11:02:31Z","timestamp":1647342151000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2790101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.2312","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}